REPL NASDAQ
Credit Risk of going bust: higher than 93% of companies Debt: 8.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.28 (down 98%), Replimune Group, Inc. would be worth roughly what it owes.
Total debt $112.0M against a stock market value of $1.17B.
Distance to default 1.09 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $42.1M (short-term plus half of long-term), stock volatility 178.7%; Altman Z'' -19.99. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Woburn, MA 01801
US
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Astley-Sparke Philip | G-Gift | 50,000 | — | 2026-08-20 |
| Hill Emily Luisa | S-Sale | 9,256 | $14.28 | 2026-08-17 |
| Patel Sushil | S-Sale | 39,341 | $12.97 | 2026-08-10 |
| Hill Emily Luisa | S-Sale | 11,448 | $12.97 | 2026-08-10 |
| Xynos Konstantinos | S-Sale | 11,447 | $12.97 | 2026-08-10 |